We reported that children with B-progenitor-cell acute lymphoblastic leukemia (BpALL) treated in the early 1980s whose lymphoblasts accumulated high levels of methotrexate (MTX) and of methotrexate polyglutamates (MTXPGs) in vitro had an improved 5-year event-free survival (EFS) (65% (standard error (s.e.) 12%) vs 22% (s.e. 9%)). We repeated this study in children with BpALL treated in the early 1990s. The major change in treatment was the addition of 12 24-h infusions of 1 g/M 2 MTX with leucovorin rescue (IDMTX). In 87 children treated on Pediatric Oncology Group (POG) study 9005 and POG 9006, the 5-year EFS for those whose lymphoblasts accumulated high levels of MTX and MTXPGs (79.2%, s.e. 8.3%) was not significantly different from that of patients with lesser accumulation of MTX and MTXPGs (77.7%, s.e. 5.4%). These findings support the notion that higher dose MTX therapy has contributed to increased cure, particularly for patients whose lymphoblasts accumulate the drug less well.
Introduction
Event-free survival (EFS) has increased progressively for children diagnosed with B-progenitor-cell acute lymphoblastic leukemia (BpALL) during the past half century. From very few survivors, the cure rate increased to 50% by 1980 and is currently 75% or more. This improvement is the result of successive studies by clinical cooperative research groups in many countries that compared chemotherapeutic regimens. 1, 2 Common to many treatment regimens for children with favorable prognostic features are an initial 4-week three-drug induction phase using vincristine, prednisone and L-asparaginase; an intensive phase of therapy with one or more drug combinations; maintenance or continuation therapy principally comprising oral 6-mercaptopurine (6-MP) and methotrexate (MTX); and intrathecal chemotherapy to prevent the development of central nervous system (CNS) leukemia. Total treatment duration is usually 30-36 months.
During the 1980s and 1990s, a postinduction intensification phase of therapy was developed and studied by many groups. [3] [4] [5] [6] [7] The Pediatric Oncology Group (POG, now part of the Children's Oncology Group, COG) investigated six to 12 infusions of intermediate-dose intravenous (i.v.) MTX (1 g/M 2 ) followed by leucovorin rescue at 2-3 week intervals (IDMTX). This treatment was relatively well tolerated and cure rates were similar to treatments that used other intensification regimens.
Lymphoblasts metabolize MTX to long-chain MTX polyglutamates (MTXPGs) containing 2-6 glutamyl residues. Total accumulation of MTXPGs is higher in BpALL than in T-cell or acute nonlymphocytic leukemia (ANLL) blasts. [8] [9] [10] [11] In addition, BpALL lymphoblasts accumulate longer-chain MTXPGs, predominantly MTXGlu 5 , compared with blasts from children with T-cell ALL or ANLL. Long-chain MTXPGs are the most cytotoxic form of MTX. 12 This enhanced ability of BpALL lymphoblasts to accumulate long-chain MTXPGs explained the effectiveness of MTX for treatment of BpALL.
In 1990, we reported the results of a study of the accumulation of MTX and MTXPGs in lymphoblasts at diagnosis from children with ALL who were diagnosed between 1980 and 1984, and did not receive continuous infusion MTX as part of therapy. Those whose lymphoblasts accumulated 4100 pmol MTX and 4500 pmol MTXPGs per 10 9 cells had a significantly better EFS than those whose lymphoblasts accumulated less (65% (standard error (s.e.) 12%) vs 22% (s.e. 9%), P ¼ 0.010). 13 Subsequently, we and others showed that hyperdiploid lymphoblasts accumulate high to very high levels of long-chain MTXPGs, [14] [15] [16] which explained the better treatment outcome of children with hyperdiploid ALL.
In this paper, we report the extent of accumulation of MTX and MTXPGs in lymphoblasts and the response to treatment in patients with BpALL treated in the early 1990s. Unlike the previous study, there was no significant difference in EFS between those with high levels of MTX and MTXPGs and those without. The improved outcome for both these groups, particularly those with reduced levels of lymphoblast MTX and MTXPGs, supports the proposition that the improved EFS in these patients is due to the addition of multiple courses of i.v. MTX.
Methods
From January 1991 to November 1994, 1931 patients older than 1 year who were newly diagnosed with BpALL were enrolled and treated on POG 9005 or POG 9006, companion front-line therapeutic studies of BpALL for standard-and increased-risk children, respectively. Standard-risk patients were defined as those aged 3.00-5.99 years with white blood cell (WBC) counts o100 000/ml, or those aged 1-11 years with WBC counts o10 000/ml and without CNS or testicular involvement. Also, a leukemic cell DNA index (DI) 41.16 placed a patient in the standard-risk group, regardless of age or WBC count. All other patients were placed in the increased-risk group.
BpALL was diagnosed by standard POG criteria. 17 Karyotype analysis was carried out in the POG Cytogenetics Reference Laboratory at the University of Alabama at Birmingham and in the Baylor Cancer Cytogenetics Laboratory, Houston, the Cytogenetics Laboratory, the University of Texas Southwestern Medical Center at Dallas and the Cytogenetics Laboratory, Medical College of Wisconsin, Milwaukee. The DI was determined at St Jude Children's Research Hospital in Memphis. 18 In this study, POG 8901, a DI 41.16 was used to assign hyperdiploidy rather than the number of chromosomes, because it was available for virtually every patient, whereas karyotyping of chromosomes showed an abnormal clone in only 62 of them (71%). were assigned to POG 9006, treatment 1. Additional details of these treatments are published elsewhere. 19, 20 The distribution of patients on treatment arms of POG 9005 and POG 9006 are shown in Table 1 .
Between April 1989 and November 1994, 138 children with BpALL who were older than 1 year were enrolled on POG 8901. In these patients, the accumulation of MTX and MTXPGs was measured in vitro in bone marrow lymphoblasts obtained at diagnosis. Of the 138 patients, 87 (63%) were enrolled on POG 9005 (57) and on POG 9006 (30) and were the subjects of this study. The characteristics of these 87 patients are shown in Table 2 , and compared with those of all patients enrolled on 9005/9006 and not POG 8901.
As delay in starting incubation decreases the ability of lymphoblasts to accumulate MTX and metabolize it to MTXPGs in vitro, patient accrual and incubation of fresh bone marrow samples with MTX was carried out at McGill University (the reference laboratory), at Midwest Children's Cancer Center, Milwaukee, WI, and at Baylor College of Medicine, Houston, TX. Details of the techniques of incubation of lymphoblasts from the patients with 1.0 mM 3 H-MTX for 24 h, of cell washing and of extraction and quantitation of MTX and MTXPGs by HPLC have been described. 14, 16 A lymphoblast MTX level 4100 pmol/10 9 cells and an MTXPG level 4500 pmol/10 9 cells were defined as high. 13 
Statistical considerations
The primary inference was to confirm the favorable prognostic significance of MTX 4100 pmol/10 9 cells and MTXPG 4500 pmol/10 9 cells, compared with one or both falling below these thresholds. Kaplan-Meier 21 estimates of 5-and 8-year EFS are provided for all POG 8901 participants who were in POG 9005 and POG 9006. s.e.'s were calculated with the method of Peto and colleagues, as described by Shuster. 22 Primary comparisons of EFS were made with the log-rank test, as described by Shuster. 22 As a secondary analysis, we conducted three other log-rank analyses to control for possible imbalance in (a) study (9005 vs 9006); (b) risk, stratified as (b1) DI 41. 16 and NCI standard-risk vs (b2) DI o1.16 and NCI standard-risk vs 
Results
The overall 5-and 8-year EFS for the 87 patients was 78.0% (s.e. 4.5%) and 72.7% (s.e. 7.8%), respectively (Table 3 ). In all, 23 patients had disease that relapsed, after 0 to 2374 days of therapy. Treatment failure occurred in 14/57 patients treated on 9005 and in 9/30 patients treated on 9006 (Table 1) . In 34 patients (39.1%), the lymphoblast level of MTX was 4100 pmol/10 9 cells. There was no significant difference in EFS in those patients, compared with those with lower levels (Table 3 ). In 41 patients (47.1%), the level of MTXPGs was 4500 pmol/10 9 cells. There was no significant difference in EFS in those patients with elevated MTXPG levels, compared with those with lower levels (Table 3) .
In all, 24 patients (27.6%) had both MTX 4100 pmol/10 9 cells and MTXPG 4500 pmol/10 9 cells. The difference in treatment outcome for these patients also was not different from those with lower levels of one or both of those parameters (P ¼ 0.73, Table 3 ). Stratifying patients by study, by risk and by treatment regimen failed to reveal a significant difference in treatment outcome in relation to lymphoblast MTX and MTXPG levels (data not shown). These results are inconclusive as to prognostic importance of these parameters. We are 95% confident that MTX o100 pmol/10 9 cells or MTXPG o500 pmol/10 9 cells have from a 22% disadvantage to an 18% advantage vs MTX 4100 pmol/10 9 cells and MTXPG 4500 pmol/10 9 cells in terms of 5-year EFS. Clinically important advantages or disadvantages cannot be ruled out.
Discussion
In a previous study, accumulation of high levels of MTX and MTXPGs in lymphoblasts in vitro was associated with a significant improvement in EFS (65% (s.e. 12%) vs 22% (s.e. 9%), P ¼ 0. 010) in 35 children with BpALL treated in the early 1980s. 13 This was particularly true for females and those who were younger and had a lower WBC count. For these 35 patients, overall 5-year EFS was 44% (s.e. ¼ 10%) (20 failures). 13 These patients were treated on various contemporary protocols, 26 (74.3%) on POG 8036. None of these patients received 24-h infusions of MTX. The 5-year EFS of patients treated on POG 8036 was 60.772.6%, 23 and for the 26 patients in our study treated on this protocol was 54%, which was similar to that of the larger population.
Changes in treatment in the decade since then resulted in improved overall 4-year EFSs of 82.1% (s.e. 2.4%) and 61.6% (s.e. 3.3%) for patients on POG 9005 and 9006, respectively. 19, 20 The 5-year EFS of patients in the present study treated on POG 9005 of 75.4% and POG 9006 of 70.0% were similar to the overall results.
The major addition to treatment in the 9005 and 9006 studies was the six to 12 i.v. courses of IDMTX. The failure to detect a difference in EFS based on the ability of lymphoblasts to accumulate MTX and MTXPGs in the present study is consistent with the notion that increased exposure of BpALL lymphoblasts to MTX overcame differences in drug metabolism, and provided cytotoxic levels of MTX and MTXPGs for most patients. Indeed, while the in vitro incubation of lymphoblasts in this study was with 1.0 mM MTX, the median levels of MTX achieved during MTX infusions in treatments 1 and 3 of POG 9005 were 10.9 and 10.6 mM, respectively. 24 Our results are consistent with those reported by Mantadakis et al, 25 who studied 52 children with BpALL who were treated with a regimen based on intensive oral MTX, similar to treatment 2 of POG 9005. 19 They found no significant difference in lymphoblast MTXPG levels, measured in vitro, between those who failed treatment and those who did not. Indeed, the estimated 5-year EFS for those with a lymphoblast MTXPG level 4500 pmol/10 9 cells was 80.0% (s.e. 7.3%) vs 90.5% (s.e. 6.4%) for those with MTXPG levels o500 pmol/10 9 cells. 
